Updates are available Correction dated 2025-07-21
Click to view Correction: https://doi.org/10.1007/s13555-025-01478-z
-
Authors
Bhatia, Neal https://orcid.org/0000-0001-7448-7809
Lynde, Charles W.
Fonacier, Luz
Shao, Liyang
Bosman, Kwinten
Korotzer, Andrew
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03428646 at ClinicalTrials.govDocuments that mention this clinical trial
Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE)
https://doi.org/10.1007/s13555-022-00742-w
Complete/Near-Complete Itch Response Observed in Patients with Moderate-to-Severe Atopic Dermatitis Initiating Dupilumab: 3-Year, Real-World, Interim Data from the PROSE Registry
https://doi.org/10.1007/s13555-025-01395-1
-
Funding
Funding for this research was provided by:
Sanofi
Regeneron Pharmaceuticals
- License Information
-
More Information
Article History
Received: 27 December 2024
Accepted: 19 March 2025
First Online: 15 April 2025
Change Date: 21 July 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s13555-025-01478-z
Declarations
:
: Neal Bhatia reports advisor or consultant funding from AbbVie, Advanced Derm Solutions, Almirall, Arcutis, Beiersdorf, Biofrontera, BMS, BI, Ferndale, Galderma, Incyte, ISDIN, J&J, La Roche-Posay, LEO, Lilly, Novartis, Ortho, Pfizer, Regeneron, Sanofi, Sun Pharma and Verrica. Charles W Lynde is an advisor, consultant and speaker for AbbVie, Altius Pharmaceuticals, Amgen, Aralez Bio, Arcutis Antiobix, Bausch Health, Bayer, BMS, BI, Cipher Pharmaceuticals, Dermavant, Fresenius Kabi, Galderma, GSK, Innovaderm, Intega, Janssen, Kyowa Kirin, La Roche-Posay, LEO Pharma, Lilly, L’Oreal, Medexus, Merck, Pediapharm, Pfizer, Procter & Gamble, Regeneron Pharmaceuticals Inc., Roche, Sanofi, Sentrex Health Solutions, Skin, Teva, Tribute Pharmaceuticals, UCB, Valeant and Viatris. Luz Fonacier reports research and educational grants (made to NYU Langone Hospital–Long Island) from AstraZeneca, Pfizer and Regeneron Pharmaceuticals Inc.; is an advisory board/consultant for AbbVie, LEO Pharma, Lilly, Pfizer and Regeneron Pharmaceuticals Inc.; was the past President (2020–2021) of American College of Allergy, Asthma & Immunology; is the Chair (2021) of American Board of Allergy and Immunology (ABAI); was the past President (2008–2010) of Long Island Allergy Society; was the past President of International Association of Filipino Allergists and Immunologists. Liyang Shao and Andrew Korotzer are employees and shareholders of Regeneron Pharmaceuticals Inc. Kwinten Bosman is an employee and a shareholder.
: The study received approval from the Institutional Review Board/Ethics Committee. All patients provided informed consent, and patient data were anonymized in compliance with the HIPAA.
